DSNKY Overview
Upcoming Projects (DSNKY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (DSNKY)
-
Discussing data from the TROPION-Breast01 phase 3 clinical trial of Datopotamab deruxtecan in breast cancer
Tickers: AZN, DSNKY
Executed On: Oct 05, 2023 at 11:00 AM EDT
Upcoming & Overdue Catalysts (DSNKY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (DSNKY)
-
Daiichi Sankyo's (DSNKY) QuANTUM-R Phase 3 trial of quizartinib in late-stage AML study data released
Ticker: DSNKY
Occurred on: May 08, 2018 -
Teva's Generic Version of Daiichi Sankyo's (DSNKY) Tribenzor Approved by FDA for Hypertension
Tickers: TEVA, DSNKY
Occurred on: Nov 07, 2016 -
Daichii Sankyo (DSNKY) Presents Phase 1 Data Evaluating DS-8201a in T-DM1 Pre-Treated Breast Cancer
Ticker: DSNKY
Occurred on: Oct 11, 2016
Strategic Initiatives (DSNKY)
-
AstraZeneca (AZN) strikes collaboration worth $6.9B to sell and develop Daiichi Sankyo's (DSNKY) HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan
Tickers: AZN, DSNKY
Announcement Date: Mar 29, 2019 -
Kite Agrees to Development and Commercialization Deal with Daiichi Sankyo (DSNKY) for Lead Product Candidate Axicabtagene Ciloleucel (KTE-C19) in Japan
Tickers: KITE, DSNKY
Announcement Date: Jan 09, 2017
